247 related articles for article (PubMed ID: 29644867)
1. Ultrasonically controlled estrone-modified liposomes for estrogen-positive breast cancer therapy.
Salkho NM; Paul V; Kawak P; Vitor RF; Martins AM; Al Sayah M; Husseini GA
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):462-472. PubMed ID: 29644867
[TBL] [Abstract][Full Text] [Related]
2. Ultrasonically controlled albumin-conjugated liposomes for breast cancer therapy.
Awad NS; Paul V; Al-Sayah MH; Husseini GA
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):705-714. PubMed ID: 30873869
[TBL] [Abstract][Full Text] [Related]
3. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
4. Targeting Breast Cancer Using Hyaluronic Acid-Conjugated Liposomes Triggered with Ultrasound.
Ben Daya SM; Paul V; Awad NS; Al Sawaftah NM; Al Sayah MH; Husseini GA
J Biomed Nanotechnol; 2021 Jan; 17(1):90-99. PubMed ID: 33653499
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound-mediated cavitation enhances the delivery of an EGFR-targeting liposomal formulation designed for chemo-radionuclide therapy.
Thomas E; Menon JU; Owen J; Skaripa-Koukelli I; Wallington S; Gray M; Mannaris C; Kersemans V; Allen D; Kinchesh P; Smart S; Carlisle R; Vallis KA
Theranostics; 2019; 9(19):5595-5609. PubMed ID: 31534505
[TBL] [Abstract][Full Text] [Related]
6. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
[TBL] [Abstract][Full Text] [Related]
7. Targeted and ultrasound-triggered drug delivery using liposomes co-modified with cancer cell-targeting aptamers and a thermosensitive polymer.
Ninomiya K; Yamashita T; Kawabata S; Shimizu N
Ultrason Sonochem; 2014 Jul; 21(4):1482-8. PubMed ID: 24418100
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen guided liposomes for targeting encapsulated anticancer agent to estrogen receptor positive breast cancer cells: in vitro and in vivo evaluation.
Jain AS; Goel PN; Shah SM; Dhawan VV; Nikam Y; Gude RP; Nagarsenker MS
Biomed Pharmacother; 2014 May; 68(4):429-38. PubMed ID: 24721327
[TBL] [Abstract][Full Text] [Related]
9. Dual cancer targeting using estrogen functionalized chitosan nanoparticles loaded with doxorubicin-estrone conjugate: A quality by design approach.
Kurmi BD; Paliwal R; Paliwal SR
Int J Biol Macromol; 2020 Dec; 164():2881-2894. PubMed ID: 32853621
[TBL] [Abstract][Full Text] [Related]
10. Ultrasound-triggered herceptin liposomes for breast cancer therapy.
Elamir A; Ajith S; Sawaftah NA; Abuwatfa W; Mukhopadhyay D; Paul V; Al-Sayah MH; Awad N; Husseini GA
Sci Rep; 2021 Apr; 11(1):7545. PubMed ID: 33824356
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of doxorubicin via estrone-appended liposomes.
Rai S; Paliwal R; Vaidya B; Khatri K; Goyal AK; Gupta PN; Vyas SP
J Drug Target; 2008 Jul; 16(6):455-63. PubMed ID: 18604658
[TBL] [Abstract][Full Text] [Related]
12. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
[TBL] [Abstract][Full Text] [Related]
13. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of the uptake and cytotoxic activity of doxorubicin in cancer cells by novel cRGD-semipeptide-anchoring liposomes.
Battistini L; Burreddu P; Sartori A; Arosio D; Manzoni L; Paduano L; D'Errico G; Sala R; Reia L; Bonomini S; Rassu G; Zanardi F
Mol Pharm; 2014 Jul; 11(7):2280-93. PubMed ID: 24819754
[TBL] [Abstract][Full Text] [Related]
15. Glycol Chitosan-Docosahexaenoic Acid Liposomes for Drug Delivery: Synergistic Effect of Doxorubicin-Rapamycin in Drug-Resistant Breast Cancer.
Kim MW; Niidome T; Lee R
Mar Drugs; 2019 Oct; 17(10):. PubMed ID: 31614820
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer.
Saha P; Fortin S; Leblanc V; Parent S; Asselin É; Bérubé G
Steroids; 2012 Sep; 77(11):1113-22. PubMed ID: 22801351
[TBL] [Abstract][Full Text] [Related]
17. Further Evolution of Multifunctional Niosomes Based on Pluronic Surfactant: Dual Active Targeting and Drug Combination Properties.
Tavano L; Mauro L; Naimo GD; Bruno L; Picci N; Andò S; Muzzalupo R
Langmuir; 2016 Sep; 32(35):8926-33. PubMed ID: 27504856
[TBL] [Abstract][Full Text] [Related]
18. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
19. Reversal of P-glycoprotein-mediated multidrug resistance by doxorubicin and quinine co-loaded liposomes in tumor cells.
Shen Q; Qiu L
J Liposome Res; 2017 Dec; 27(4):293-301. PubMed ID: 27581212
[TBL] [Abstract][Full Text] [Related]
20. One platform comparison of estrone and folic acid anchored surface engineered MWCNTs for doxorubicin delivery.
Mehra NK; Jain NK
Mol Pharm; 2015 Feb; 12(2):630-43. PubMed ID: 25517904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
